1. Seroprevalence and Antibody Responses to SARS-CoV-2 in Adults and Children: Implications for Vaccination Strategies.
- Author
-
Alemán, Margarita Valdés, Llamas, Beatriz, Arias, Eduardo, López, Vanessa, Esquivel, Fernando, Del Río, Carlos N., and González, Ramón A.
- Subjects
- *
SEROPREVALENCE , *ANTIBODY formation , *CORONAVIRUS diseases - Abstract
This study assessed the seroprevalence of SARS-CoV-2 and antibody responses in a high-risk adult population and hospitalized children in the state of Morelos. An ELISA test utilizing the SARS-CoV-2 spike protein’s RBD domain was employed to detect IgG, IgM, and IgA antibodies. Among adults, before vaccination campaigns (n = 114), 26.3 % tested positive for IgG, while IgM and IgA were detected in 19.3 % and 13.2 %, respectively. The impact of Pfizer-BioNTech (BNT162b2) vaccination was analyzed, revealing significant increases in antibody levels following the second dose. Subsequently, participants receiving third doses from different vaccines exhibited comparable or higher IgG and IgM levels. IgA levels varied, with a subset reaching high levels only after receiving the booster dose. Children, before vaccination campaigns (n = 115), displayed 56.5 % IgG seropositivity, despite minimal reported COVID-19 cases. Elevated MIS-C/Kawasaki syndrome diagnoses (15 %) prompted a need for pediatric diagnosis focus. Comparative analysis of antibodies’ levels in seropositive adults and children showed higher responses in adults both after infection (IgG: r = 0.42, p < 0.001; IgM: r = 0.63, p < 0.001) and after application of two vaccine doses (IgG: r = 0.52, p < 0.001; IgM: r = 0.57, p < 0.001; IgA: r = 0.26, p < 0.001). These findings underscore the necessity for continued antibody response monitoring post-vaccination in children and emphasize the importance of tailored vaccination strategies and diagnostic prioritization to address SARS-CoV-2 immunity in diverse populations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF